Article
Oncology
Meredith C. Mason, Maciej Krasnodebski, Caitlin A. Hester, Anai N. Kothari, Caeli Barker, Yujiro Nishioka, Yi-Ju Chiang, Timothy E. Newhook, Ching-Wei D. Tzeng, Yun Shin Chun, Jean-Nicolas Vauthey, Hop S. Tran Cao
Summary: In patients with colorectal liver metastases, mixed pathologic response is possible in multiple metastases. Patients with mixed response have higher survival rates compared to other pathologic responses, suggesting that the greatest response achieved in any metastasis is the best predictor of survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Carolin Czauderna, Kim Luley, Nikolas von Bubnoff, Jens U. Marquardt
Summary: Liver metastases are the most common site of metastasis in colorectal cancer. Current treatment approaches involve systemic therapies and surgical/interventional strategies, with the use of predictive and prognostic biomarkers leading to improved survival rates. Treatment selection based on patient status, tumor characteristics, and molecular/genetic status is recommended for better outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
C. Villard, M. Habib, C. Nordenvall, P. J. Nilsson, C. Jorns, E. Sparrelid
Summary: Conversion therapy can offer a survival benefit in selected patients, but the majority of patients still cannot undergo liver resection treatment.
Article
Surgery
Kozo Kataoka, Kanae Takahashi, Jiro Takeuchi, Kazuma Ito, Naohito Beppu, Wim Ceelen, Yukihide Kanemitsu, Yoichi Ajioka, Itaru Endo, Kiyoshi Hasegawa, Keiichi Takahashi, Masataka Ikeda
Summary: This study compared the correlation between recurrence-free survival (RFS) and overall survival (OS) in patients who underwent surgery for colorectal liver metastases. The results showed a strong correlation between RFS and OS, regardless of the adjuvant chemotherapy regimen used.
BRITISH JOURNAL OF SURGERY
(2023)
Article
Medicine, General & Internal
Karen Bolhuis, Iris van 't Erve, Clinton Mijnals, Pien M. Delis-Van Diemen, Joost Huiskens, Aysun Komurcu, Marta Lopez-Yurda, Daan van den Broek, Rutger-Jan Swijnenburg, Gerrit A. Meijer, Cornelis J. A. Punt, Remond J. A. Fijneman
Summary: The detection of postoperative ctDNA after resection of colorectal cancer liver metastases is a promising prognostic factor for recurrence-free survival, and is highly correlated with pathological response.
Editorial Material
Oncology
Kazunari Sasaki, Luis I. Ruffolo, Michelle H. Kim, Masato Fujiki, Koji Hashimoto, Yuki Imaoka, Marc L. Melcher, Federico N. Aucejo, Koji Tomiyama, Roberto Hernandez-Alejandro
Summary: This study summarizes the characteristics and outcomes of liver transplantation for nonresectable colorectal liver metastases (CRLM) in 46 patients. It suggests a growing interest in high-volume U.S. transplant centers for this indication.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Feng-Lin Chen, Yan-Yan Wang, Wei Liu, Bao-Cai Xing
Summary: This study assessed the efficacy of neoadjuvant chemotherapy (NAC) in resectable colorectal liver metastases (CRLM) patients with high clinical risk scores (CRS) after balancing baseline characteristics by propensity score matching (PSM). The results showed that NAC improved overall survival (OS) and resulted in shorter postoperative hospital stays.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Liam F. Spurr, Carlos A. Martinez, Rohan R. Katipally, Soumya C. Iyer, Sian A. Pugh, John A. Bridgewater, John N. Primrose, Enric Domingo, Timothy S. Maughan, Michael D'Angelica, Mark Talamonti, Mitchell C. Posner, Philip P. Connell, Ralph R. Weichselbaum, Sean P. Pitroda
Summary: Personalized treatment approaches are crucial for patients with limited liver metastases from colorectal cancer. A study involving three large cohorts found that a proliferative subtype associated with elevated CIN70 scores is linked to immune exclusion, increased metastatic proclivity, and inferior overall survival in colorectal liver metastases. However, high CIN70 scores also create a therapeutic vulnerability to DNA-damaging therapies, leading to improved treatment responses. CIN70 could potentially serve as a candidate biomarker to personalize systemic treatment options for patients with metastatic colorectal cancer.
NPJ PRECISION ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Harufumi Maki, Antony Haddad, Reed I. Ayabe, Mateo Lendoire, Isha Khanduri, Dipen M. Maru, Jean-Nicolas Vauthey
Summary: The aim of this study was to evaluate the impact of known gene alterations on pathologic response and survival in patients with colorectal liver metastases. The results showed that an oxaliplatin-containing regimen, a bevacizumab-containing regimen, and TP53 alteration were independently associated with a major pathologic response. Patients with TP53 wild-type and major pathologic response, as well as those with TP53 alteration and major pathologic response, had significantly better overall survival compared to those with minor pathologic response. Further research focusing on the association between TP53 and pathologic response and survival can provide insights into the role of TP53 in colorectal liver metastases.
JOURNAL OF GASTROINTESTINAL SURGERY
(2023)
Article
Oncology
Andrew A. Gumbs, Roland Croner, Eric Lorenz, Andrea Benedetti Cacciaguerra, Tzu-Jung Tsai, Lee Starker, Joe Flanagan, Ng Jing Yu, Elie Chouillard, Mohammad Abu Hilal
Summary: This study evaluates the long-term outcomes of minimally invasive liver resection for colorectal liver metastases. The results show that laparoscopic and robotic approaches have similar survival rates and recurrence-free survival rates compared to open hepatectomy.
Review
Oncology
Annabel Jones, Alasdair Findlay, Stephen R. Knight, Jonathan Rees, David O'Reilly, Robert P. Jones, Samir Pathak
Summary: There is wide variation in follow-up methods and outcome reporting for patients with colorectal liver metastases after hepatectomy. There is currently no strong evidence to support intensive follow-up, and the benefits of long-term follow-up are unknown due to a lack of patient-centered data. Future research should focus on high-quality prospective studies.
Article
Oncology
Astrid Bauschke, Annelore Altendorf-Hofmann, Merten Homman, Thomas Manger, Joerg Pertschy, Herry Helfritzsch, Hubert Goebel, Utz Settmacher
Summary: The study retrospectively analyzed data from 637 patients between 1995 and 2018, finding that different factors affect the survival rates of patients with different tumor entities, and the Adam score can identify risk factors for most but not all tumor entities.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Review
Medicine, General & Internal
Meritxell Molla, Julen Fernandez-Plana, Santiago Albiol, Constantino Fondevila, Ivan Vollmer, Carla Cases, Angeles Garcia-Criado, Jaume Capdevila, Carles Conill, Yliam Fundora, Carlos Fernandez-Martos, Estela Pineda
Summary: The prognosis for oligometastatic colorectal cancer has improved due to recent advances in new techniques and approaches such as new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy. Factors to consider when deciding on the best approach include tumor factors, patient factors, and physician factors. These advances have presented challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Joy Sarkar, Kristopher Attwood, Roderich E. Schwarz
Summary: This study reveals a correlation between perioperative chemotherapy and superior overall survival (OS) in patients with liver-only colorectal cancer liver metastases (CRLM), and shows that resection of the metastatic site was linked to better OS. Despite obvious cohort heterogeneity, the data can support a resection approach with additional, preferably peri- or preoperative systemic therapy for patients with CRLM.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Florian E. Buisman, Wills F. Filipe, Nancy E. Kemeny, Raja R. Narayan, Rami M. Srouji, Vinod P. Balachandran, Thomas Boerner, Jeffrey A. Drebin, William R. Jarnagin, T. Peter Kingham, Alice C. Wei, Dirk J. Grunhagen, Cornelis Verhoef, Bas Groot Koerkamp, Michael I. D'Angelica
Summary: This study investigated the effectiveness of adjuvant hepatic arterial infusion pump (HAIP) chemotherapy after complete resection or ablation of recurrent colorectal liver metastases and found that adjuvant HAIP is associated with superior hepatic disease-free survival and overall survival.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Benny Johnson, Dong Yang, Hiba I. Dada, Leylah Drusbosky, Scott Kopetz
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Oscar Villarreal, Fadl A. Zeineddine, Ray Chacko, Christine Megerdichian Parseghian, Benny Johnson, Jason Willis, Michael Sangmin Lee, Van K. Morris, Arvind Dasari, Kanwal Pratap Singh Raghav, Michael J. Overman, Y. Nancy You, Yinghong Wang, Dipen M. Maru, John Paul Y. C. Shen, Scott Kopetz
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Agop Philip Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M. Boland, Dustin A. Deming, Aaron James Scott, Howard John Lim, Theodore S. Hong, Norman Wolmark, Thomas J. Georgenrg
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Arvind Dasari, Maen Abdelrahim, Jared David Acoba, Krishna Chaitanya Alluri, Tomislav Dragovich, Syed Mohammad Ali Kazmi, Benjamin Leon Musher, Ryan Sun, Lucas Wong, Y. Nancy You, Robert Anthony Zaiden, Scott Kopetz
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Letter
Oncology
Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Summary: KRAS(G12C) mutation is associated with tumor identification and its sensitivity to current treatments. This study demonstrates the synergistic effect of sotorasib and DT2216 combination therapy on certain KRAS(G12C) tumor cell lines, leading to enhanced efficacy in treating these tumors.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Marwan Fakih, Huakang Tu, Hil Hsu, Shivani Aggarwal, Emily Chan, Marko Rehn, Victoria Chia, Scott Kopetz
Summary: This article describes clinicopathologic characteristics, treatment patterns, overall survival, and real-world progression-free survival in patients with metastatic colorectal cancer and specific KRAS mutations. The results show that patients with the KRAS p.G12C mutation have poor treatment outcomes and potential prognostic implications.
Article
Oncology
Van Morris, Bryan Kee, Michael Overman, Arvind Dasari, Kanwal Raghav, Benny Johnson, Christine Parseghian, Robert A. Wolff, Naveen Garg, Cathy Eng, Scott Kopetz
Summary: The study analyzed the characteristics and survival rates of patients with BRAF(V60)(0E) mutated metastatic CRC, finding significant differences in clinical/pathologic features between patients with favorable and poor outcomes, including hepatic involvement, metachronous metastases, and treatment modalities. While the overall prognosis for most patients with BRAF(V60)(0E) mutated metastatic CRC remains poor, a small subset may achieve exceptionally favorable long-term survival.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Nicky van der Heijde, Frederique L. Vissers, Alberto Manzoni, Giuseppe Zimmitti, Joaquim Balsells, Frederik Berrevoet, Bergthor Bjornsson, Peter van den Boezem, Ugo Boggi, Svein O. Bratlie, Fernando Burdio, Andrea Coratti, Mathieu D'Hondt, Carlos D. Del Pozo, Safi Dokmak, Regis Fara, Mehmet F. Can, Sebastiaan Festen, Antonello Forgione, Claus Fristrup, Sebastien Gaujoux, Bas Groot Koerkamp, Thilo Hackert, Igor E. Khatkov, Tobias Keck, Hanna Seppanen, Daan Lips, Misha Luyer, Gabriella Pittau, Manuel Maglione, I. Quintus Molenaar, Patrick Pessaux, Geert Roeyen, Olivier St-Marc, Santiago S. Cabus, Hjalmar van Santvoort, George van der Schelling, Mario Serradilla-Martin, Francois-regis Souche, Miguel A. Suarez Munoz, Marco Marino, Marc G. Besselink, Mohammed Abu Hilal
Summary: The E-MIPS registry collects data on laparoscopic and robotic minimally invasive pancreatic surgery (MIPS) across Europe. This study analyzed the first year of the registry and found that MIDP was performed in about half of the patients, mainly using laparoscopy, while MIPD was performed in about a quarter of the patients, more often using the robotic approach. There were only a minority of centers that met the Miami guideline volume criteria for MIPD.
Article
Oncology
Kanwal Raghav, Fang-Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz-Josef Lenz, Scott Kopetz
Summary: Clinical trial updates allow for dissemination of additional results from studies where the primary end point has already been reported. This study aimed to determine the prevalence of acquired genomic alterations (Acq-GAs) on anti-EGFR-chemotherapy compared to anti-VEGF-chemotherapy and later-line anti-EGFR-antibody therapy in metastatic colorectal cancer (mCRC). The findings indicate divergent resistance mechanisms with rare occurrence of Acq-GAs with up-front use of anti-EGFR-chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Veronika Fedirko, Scott Kopetz, Carrie R. Daniel
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Oncology
Madhulika Eluri, Scott Kopetz, Christine M. Parseghian
Summary: The use of serial ctDNA in metastatic colorectal cancer has the potential to refine patient selection, reduce chemotherapy toxicity, and assess emerging resistance mechanisms for novel therapeutic strategies. However, important questions remain regarding its validation as a predictive biomarker of treatment response.
CLINICAL CANCER RESEARCH
(2023)
Letter
Oncology
Kanwal Raghav, Scott Kopetz, Ying Yuan
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Blessie Elizabeth Nelson, Apostolia M. Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K. Sood, Jordi Rodon, Daniel D. Karp, George Blumenschein, Scott Kopetz, Shubham Pant, Sarina A. Piha-Paul
Summary: This study evaluated the combination of bevacizumab, temsirolimus, and valproic acid in patients with advanced malignancies and found modest efficacy but significant toxicity. The study is the first to evaluate this combination and suggests potential for anticancer activity, but careful management of toxicity is necessary for future development.
Article
Oncology
Tijs J. Hoogteijling, Jasper P. Sijberden, John N. Primrose, Victoria Morrison-Jones, Sachin Modi, Giuseppe Zimmitti, Marco Garatti, Claudio Sallemi, Mario Morone, Mohammad Abu Hilal
Summary: This study evaluated the safety and feasibility of Laparoscopic right hemihepatectomy (L-RHH) after Future liver remnant modulation (FLRM), compared to ex novo L-RHH. The results showed that L-RHH after FLRM is more technically complex, with longer operative time and Pringle duration, but it remains safe and feasible in experienced hands.